Question-and-Answer Session
Operator
At this time, (Operator Instructions). Your first question comes from the line of Eric Varma with Leerink Swann.
Eric Varma - Leerink Swann
Hi, great job on earnings this morning. This is Eric Varma in place of Joe Schwartz. My first question is can you kind of give us a little bit more details on the rest of the world partnership for Denufosol?
Dr. Christy L. Schaffer, Ph.D.
Sure, Eric. Good morning. How are you?
Eric Varma - Leerink Swann
Very well, thanks.
Dr. Christy L. Schaffer, Ph.D.
The question relates to our ongoing potential partnering discussions regarding Denufosol. I want to mention and be clear again that we believe this is a very important asset for Inspire and therefore, we fully expect to retain rights in North America, both U.S. and Canada, in terms of commercialization of this product.
We have been in ongoing discussions with multiple potential partners that are interested in gaining access to life outside of North America. And the update this morning is simply that those talks are ongoing. We’re very actively talking to a number of parties at this time.
Eric Varma - Leerink Swann
Okay, that’s helpful. And then I was also wondering for TIGER-2, why did you decide to enroll outside of the U.S. considering that there’s already a lot of excitement among doctors and patients within the U.S.?
Dr. Christy L. Shaffer, Ph.D.
Well, actually we had included Canadian sites in TIGER-1 and you probably know that Dr. Felix Ratjen, who is the PI for TIGER-2, is actually a very important Canadian investigator at Children’s Sick Hospital in Toronto. There’s been a lot of enthusiasm across the world for the new facility.
In fact there are many, many European investigators who are interested in participating. At this point we have limited it to, as you heard this morning, North America, Australia, New Zealand, but we could have obviously included a larger number of sites. At this point we’re thinking that we’re going to wait until we have the partner in place to determine what we might do more broadly across Europe.
In Europe there’re about 250 CF treatment centers that have about 35,000 patients that are treated across the continent of Europe.
Eric Varma - Leerink Swann
Okay, that makes sense. And then lastly, what more cuts can we expect in the TIGER-1 data? Are there any more subgroup analyses to be expected?
- To read the full transcript on Seeking Alpha, click here »
